Clinical Trial Update: Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 trial of MEDI-522 in active rheumatoid arthritis patients suboptimally responding to methotrexate reports on disease activity and progression of joint d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MEDI-522

Snippet

Sponsor: MedImmune LLC | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED